MX2013013437A - 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico. - Google Patents

4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.

Info

Publication number
MX2013013437A
MX2013013437A MX2013013437A MX2013013437A MX2013013437A MX 2013013437 A MX2013013437 A MX 2013013437A MX 2013013437 A MX2013013437 A MX 2013013437A MX 2013013437 A MX2013013437 A MX 2013013437A MX 2013013437 A MX2013013437 A MX 2013013437A
Authority
MX
Mexico
Prior art keywords
benzimidazol
methylpiperazin
fluoro
amino
quinoli
Prior art date
Application number
MX2013013437A
Other languages
English (en)
Inventor
Michael Shi
Michael Wick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013013437(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013013437A publication Critical patent/MX2013013437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe un método para reducir los tumores sólidos en un sujeto que tenga un carcinoma adenoide quístico, el cual comprende administrar una cantidad terapéuticamente efectiva de la 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1H-bencimidaz ol-2-il]-1H-quinolin-2-ona o de una sal farmacéuticamente aceptable de la misma.
MX2013013437A 2011-05-19 2012-05-18 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico. MX2013013437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487939P 2011-05-19 2011-05-19
PCT/US2012/038490 WO2012158994A1 (en) 2011-05-19 2012-05-18 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma

Publications (1)

Publication Number Publication Date
MX2013013437A true MX2013013437A (es) 2013-12-06

Family

ID=46168643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013437A MX2013013437A (es) 2011-05-19 2012-05-18 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.

Country Status (17)

Country Link
US (1) US20150182525A1 (es)
EP (1) EP2709729A1 (es)
JP (1) JP2014515353A (es)
KR (1) KR20140023358A (es)
CN (1) CN103547315A (es)
AU (1) AU2012255148A1 (es)
BR (1) BR112013029246A2 (es)
CA (1) CA2834699A1 (es)
CL (1) CL2013003306A1 (es)
IL (1) IL229073A0 (es)
MA (1) MA35156B1 (es)
MX (1) MX2013013437A (es)
RU (1) RU2013156378A (es)
SG (1) SG194445A1 (es)
TN (1) TN2013000414A1 (es)
WO (1) WO2012158994A1 (es)
ZA (1) ZA201307411B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA036592B1 (ru) 2012-06-13 2020-11-26 Инсайт Холдингс Корпорейшн Замещенные трициклические соединения как ингибиторы fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
KR102238677B1 (ko) 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR102632018B1 (ko) 2015-02-20 2024-02-02 인사이트 홀딩스 코포레이션 Fgfr 저해제로서의 이환식 복소환
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
CA3099287A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1650203E (pt) 2000-09-11 2008-05-13 Novartis Vaccines & Diagnostic Processo de preparação de derivados de benzimidazol-2-ilquinolinona
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
JP5371246B2 (ja) * 2005-01-27 2013-12-18 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移した腫瘍の治療
CA2608171C (en) * 2005-05-13 2014-02-04 Novartis Ag Use of quinolinone compounds for treating drug resistant cancers
US20110178097A1 (en) 2005-05-23 2011-07-21 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
ES2336832T3 (es) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
AU2011240001B2 (en) * 2010-04-16 2014-05-08 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
CL2013003306A1 (es) 2014-07-11
MA35156B1 (fr) 2014-06-02
AU2012255148A1 (en) 2013-11-07
KR20140023358A (ko) 2014-02-26
JP2014515353A (ja) 2014-06-30
BR112013029246A2 (pt) 2017-02-14
ZA201307411B (en) 2014-06-25
EP2709729A1 (en) 2014-03-26
SG194445A1 (en) 2013-12-30
IL229073A0 (en) 2013-12-31
TN2013000414A1 (en) 2015-03-30
RU2013156378A (ru) 2015-06-27
WO2012158994A1 (en) 2012-11-22
NZ616345A (en) 2015-10-30
CA2834699A1 (en) 2012-11-22
US20150182525A1 (en) 2015-07-02
CN103547315A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2015017964A (es) Inhibidores de bromodominio.
NZ706836A (en) Methods of treating cancer
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MY165826A (en) Pharmaceutical composition
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2016002302A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
UA115250C2 (uk) Фармацевтичні комбінації
IL229424A0 (en) Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
HK1258235A1 (zh) 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑